TG Therapeutics, Inc. (TGTX) Financials
TGTX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 1.5 billion | 945.7 million |
| Dec. 31, 2025 | 1.1 billion | 415.2 million |
| Sept. 30, 2025 | 1.0 billion | 417.8 million |
| June 30, 2025 | 702.6 million | 426.2 million |
TGTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -17.9 million | 20.0 million |
| Dec. 31, 2025 | 19.6 million | 15.7 million |
| Sept. 30, 2025 | -23.2 million | 17.7 million |
| June 30, 2025 | 7.4 million | 16.4 million |
TGTX Net Income
No data available :(
TGTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 514.4 million | 745.1 million | 6.6 million |
| Dec. 31, 2025 | 142.0 million | 252.7 million | 7.0 million |
| Sept. 30, 2025 | 131.6 million | 245.3 million | 8.4 million |
| June 30, 2025 | 251.9 million | 245.0 million | 8.7 million |
TGTX Shares Outstanding
TGTX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 51000 | 43.5 million | 73.1 million | - |
| Dec. 31, 2025 | 67000 | 41.2 million | 62.7 million | - |
| Sept. 30, 2025 | 80000 | 40.9 million | 63.3 million | - |
| June 30, 2025 | 42000 | 31.8 million | 55.6 million | - |
TGTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 204.9 million | 33.5 million |
| Dec. 31, 2025 | 192.6 million | 38.1 million |
| Sept. 30, 2025 | 161.7 million | 28.2 million |
| June 30, 2025 | 141.1 million | 18.9 million |
TGTX Revenue by Segment
Graph available only for paid members. Upgrade to see it.
TGTX
Price: $56.04
52 week price:
Payout Ratio Range:
Earnings Per Share: 2.86 USD
P/E Ratio: 15.08
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 2.7 million
Ebitda: -31.6 millionMarket Capitalization: 8.9 billion